PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31053148-14	2019	Sorafenib induced translocation of miR-21 to the nucleus, where it promoted the expression of SNHG1, resulting in upregulation of SLC3A2, leading to the activation of Akt pathway.	Sorafenib	0-9	microRNA 21	Homo sapiens	35-41	
34852817-0	2021	Correction to: LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.	Sorafenib	43-52	microRNA 21	Homo sapiens	125-131	
31053148-16	2019	CONCLUSIONS: The present study has demonstrated that lncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and its nuclear expression is promoted by miR-21, whose nuclear translocation is induced by sorafenib.	Sorafenib	81-90	microRNA 21	Homo sapiens	174-180	
31053148-16	2019	CONCLUSIONS: The present study has demonstrated that lncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and its nuclear expression is promoted by miR-21, whose nuclear translocation is induced by sorafenib.	Sorafenib	224-233	microRNA 21	Homo sapiens	174-180	
29895198-6	2019	We proposed that GAS5 was responsible for sorafenib resistance in RCC cells and GAS5 exerted its function through the miR-21/ SOX5 axis.	Sorafenib	42-51	microRNA 21	Homo sapiens	118-124	
29895198-0	2019	Long non-coding RNA GAS5 sensitizes renal cell carcinoma to sorafenib via miR-21/SOX5 pathway.	Sorafenib	60-69	microRNA 21	Homo sapiens	74-80	
26311740-12	2015	MiR-21 could serve as a therapeutic target for overcoming sorafenib resistance in the treatment of HCC.	Sorafenib	58-67	microRNA 21	Homo sapiens	0-6	
26311740-0	2015	MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.	Sorafenib	16-25	microRNA 21	Homo sapiens	0-6	
26311740-6	2015	Differential screening of miRNAs showed higher levels of miR-21 in sorafenib-resistant HCC cells.	Sorafenib	67-76	microRNA 21	Homo sapiens	57-63	
26311740-7	2015	Exposure of HCC cells to sorafenib led to an increase in miR-21 expression, a decrease in PTEN expression and sequential Akt activation.	Sorafenib	25-34	microRNA 21	Homo sapiens	57-63	
26311740-8	2015	Transfection of miR-21 mimics in HCC cells restored sorafenib resistance by inhibiting autophagy.	Sorafenib	52-61	microRNA 21	Homo sapiens	16-22	
26311740-9	2015	Anti-miR-21 oligonucleotides re-sensitized sorafenib-resistant cells by promoting autophagy.	Sorafenib	43-52	microRNA 21	Homo sapiens	5-11	
26311740-10	2015	Inhibition of miR-21 enhances the efficacy of sorafenib in treating sorafenib-resistant HCC tumors in vivo.	Sorafenib	46-55	microRNA 21	Homo sapiens	14-20	
26311740-10	2015	Inhibition of miR-21 enhances the efficacy of sorafenib in treating sorafenib-resistant HCC tumors in vivo.	Sorafenib	68-77	microRNA 21	Homo sapiens	14-20	
26311740-11	2015	We conclude that miR-21 participates in the acquired resistance of sorafenib by suppresing autophagy through the Akt/PTEN pathway.	Sorafenib	67-76	microRNA 21	Homo sapiens	17-23	
25721136-7	2014	The suppressive effect of combining matrine and sorafenib was significantly reduced by miRNA-21 overexpression or PTEN inhibition.	Sorafenib	48-57	microRNA 21	Homo sapiens	87-95	
25721136-8	2014	CONCLUSION: Matrine in combination with sorafenib leads to increased cytotoxic effects against HCC cells, at least partially, via the suppression of miRNA-21 and the subsequent induction of PTEN.	Sorafenib	40-49	microRNA 21	Homo sapiens	149-157